MedTrace Logo

Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms

NCT04858893 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 562

Last updated 2021-05-12

No results posted yet for this study

Summary

Based on a prospectively collected data analysis, a new tool, namely CoMDA (Cognition in Movement Disorders Assessment) is developed by merging each item of Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) and Frontal Assessment Battery (FAB). A machine learning, able to classify the cognitive profile and predict patients' at risk of dementia, is created.

Conditions

  • Primary Parkinsonism
  • Secondary Vascular Parkinson Disease
  • Multiple System Atrophy
  • Supranuclear Palsy, Progressive

Interventions

DIAGNOSTIC_TEST

CoMDA associated with Neural Net 91 classificator

Sponsors & Collaborators

  • Ospedale di Vipiteno-Sterzing (SABES-ASDAA)

    collaborator UNKNOWN

  • Ospedale Generale Di Zona Moriggia-Pelascini

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-02-01
Completion
2020-08-31

Countries

  • Italy

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04858893 on ClinicalTrials.gov